Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 10864252
Anti-SSX-2 T cell receptors and related materials and methods of use
granted -
US 10865389
DNA vaccines against foot-and-mouth disease virus
granted -
US 10858634
Vaccines and pharmaceutical compositions against foot-and-mouth disease virus
granted -
US 10857265
Injectable composition for in-situ repair and regeneration of an injured ligament or tendon and methods of use
granted -
US 10857174
Morpholino oligonucleotides useful in cancer treatment
granted -
US 10857219
Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
granted -
US 10858633
Method for producing foot-and-mouth disease virus (FMDV) viral proteins utilizing a modified FMDV 3C protease
granted -
US 10849960
Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
granted -
US 10849970
Antibody evolution immunogens
granted -
US 10849912
Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
granted -
US 10849896
Sortilin-binding small molecules for increasing glucose uptake
granted -
US 10849935
Method to suppress the systemic toxicity of chemotherapeutic drugs
granted -
US 10849975
Multivalent vaccines for rabies virus and filoviruses
granted -
US 10844387
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10842823
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted -
US 10837019
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10837003
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
granted -
US 10836759
Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
granted -
US 10835755
Method of using laser-induced optoacoustics for the treatment of drug-resistant microbial infections
granted -
US 10835593
Modified anthrax toxin protective antigen
granted -
US 10836721
Thalidomide analogs and methods of use
granted -
US 10835549
Polyplexes
granted -
US 10828364
Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions
granted -
US 10830678
Photo-controlled removal of targets in vitro and in vivo
granted -
US 10829769
Chimeric antigen receptors targeting b-cell maturation antigen
granted -
US 10828304
Compositions and methods for white to beige adipogenesis
granted -
US 10829767
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10829768
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10829770
Fusion proteins containing luciferase and a polypeptide of interest
granted -
US 10822588
Agents and methods to elicit anti-tumor immune response
granted -
US 10822608
Oligonucleotide analogues targeting human LMNA
granted -
US 10815488
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10815487
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10815301
Anti-CD30 chimeric antigen receptors
granted -
US 10813913
Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
granted -
US 10815295
Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein
granted -
US 10815285
Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
granted -
US 10813952
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
granted -
US 10813993
Display platform from bacterial spore coat proteins
granted -
US 10808010
Peptide inhibitors of phosphoglycerate mutase and methods of use
granted -
US 10808225
Use of PDL1 expressing cells to convert T cells into regulatory T cells
granted -
US 10808011
Recombinant HIV-1 envelope proteins and their use
granted -
US 10799580
Expression vector delivery system and use thereof for inducing an immune response
granted -
US 10799590
Compositions containing a bitter tastant and at least one sophorolipid, and methods of reducing bitter taste attributed to a bitter tastant in an edible composition
granted -
US 10799584
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
granted -
US 10793865
Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions
granted -
US 10792274
Dehydroacetic acid (DHAA) and derivative for uses in treating cancer
granted -
US 10787419
Cannabinoid receptor mediating iminopyrazole compounds
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory